Actinium Pharmaceuticals, Inc.
ATNM
$1.25
$0.021.29%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 35.09M | 90.00K | 90.00K | 90.00K | -- |
| Total Revenue | 35.09M | 90.00K | 90.00K | 90.00K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 35.09M | 90.00K | 90.00K | 90.00K | -- |
| SG&A Expenses | 7.41M | 7.98M | 15.21M | 15.79M | 17.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.53M | 25.60M | 36.34M | 37.43M | 44.25M |
| Operating Income | 9.56M | -25.51M | -36.25M | -37.34M | -44.25M |
| Income Before Tax | 11.31M | -23.47M | -33.89M | -34.60M | -41.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.31 | -23.47 | -33.89 | -34.60 | -41.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.31M | -23.47M | -33.89M | -34.60M | -41.04M |
| EBIT | 9.56M | -25.51M | -36.25M | -37.34M | -44.25M |
| EBITDA | 10.27M | -24.87M | -35.59M | -36.67M | -43.58M |
| EPS Basic | 0.36 | -0.75 | -1.09 | -1.11 | -1.32 |
| Normalized Basic EPS | 0.22 | -0.47 | -0.68 | -0.69 | -0.82 |
| EPS Diluted | 0.36 | -0.75 | -1.09 | -1.11 | -1.32 |
| Normalized Diluted EPS | 0.22 | -0.47 | -0.68 | -0.69 | -0.82 |
| Average Basic Shares Outstanding | 125.03M | 124.83M | 124.78M | 124.79M | 124.67M |
| Average Diluted Shares Outstanding | 125.04M | 124.83M | 124.78M | 124.79M | 124.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |